GX 301

Drug Profile

GX 301

Alternative Names: Telomerase peptide cancer vaccine - Genovax

Latest Information Update: 25 Sep 2015

Price : $50

At a glance

  • Originator Genovax
  • Developer Genovax; Mediolanum
  • Class Cancer vaccines; Peptide vaccines; Peptides; Vaccines
  • Mechanism of Action CD4-positive T lymphocyte stimulants; CD8 positive T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Prostate cancer
  • Discontinued Renal cancer

Most Recent Events

  • 01 Nov 2014 Phase-II clinical trials in Prostate cancer in Italy (Intradermal) (NCT02293707)
  • 03 Dec 2012 GX 301 licensed to Mediolanum Farmaceutici worldwide
  • 01 Feb 2012 Genovax completes a phase I/II trial in Prostate cancer and Renal cancer in Italy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top